One of the most common treatments for obstructive sleep apnea is continuous positive airway pressure (CPAP) applied by ... but there are also bundles for ResMed AirSense 10 ($339), Fisher ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

Q2 revenue rose 10.2% year over year ... devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining technological ...

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital ... and expand its market reach. ResMed's 10.2% revenue jump in Q2 was ...

CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...